References
1.https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020(Accessed 27-Mar-2020).
2. https://www.worldometers.info/coronavirus/ (Accessed 15-May-2020).
3. Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical
features of the emerging 2019 novel coronavirus pneumonia (COVID-19)
implicate special control measures. J Med Virol. 2020 Mar 5. doi:
10.1002/jmv.25748.
4. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human
respiratory disease in China. Nature. 2020;579(7798):265-269.
5. Abassi ZA, Skorecki K, Heyman SN, Kinaneh S, Armaly Z. Covid-19
infection and mortality - A physiologist’s perspective enlightening
clinical features and plausible interventional strategies. Am J Physiol
Lung Cell Mol Physiol. 2020 Mar 24.doi:10.1152/ajplung.00097.2020.
6. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic
treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020
Apr 13. doi: 10.1001/jama.2020.6019.
7. Lupia T, Scabini S, Mornese Pinna S, Di Perri G, De Rosa FG, Corcione
S. 2019 novel coronavirus (2019-nCoV) outbreak: A new challenge. J Glob
Antimicrob Resist. 2020;21:22-27.
8. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its
effects in coronavirus disease 2019 patients: A systematic review and
meta-analysis. Int J Infect Dis. 2020;94:91-95.
9. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and
diabetes mellitus at increased risk for COVID-19 infection? Lancet
Respir Med. 2020 Mar 11. pii: S2213-2600(20)30116-8. doi:
10.1016/S2213-2600(20)30116-8.
10. Halpin D, Faner R, Sibila O, Badia J, Agusti A. Do chronic
respiratory diseases or their treatment affect the risk of SARS-CoV-2
infection? Lancet Respir Med 2020 April 3, 2020.https://doi.org/10.1016/S2213-2600(20)30167-3.
11. Wu Z, McGoogan JM. Characteristics of and important lessons from the
Coronavirus Disease 2019 (COVID-19) outbreak in China - Summary of a
report of 72 314 cases from the chinese Center for Disease Control and
Prevention. JAMA. 2020;323(13):1239-1242.
12. Lu X, Zhang L, Du H, et al; Chinese Pediatric Novel Coronavirus
Study Team. SARS-CoV-2 infection in children. N Engl J Med. 2020 Mar 18.
doi: 10.1056/NEJMc2005073.
13. Zheng F, Liao C, Fan QH, et al. Clinical characteristics of children
with Coronavirus Disease 2019 in Hubei, China. Curr Med Sci.
2020;40(2):275-280.
14. Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children
in China. Pediatrics. 2020;145(6):e20200702.
15. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140
patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020 Feb 19.
doi: 10.1111/all.14238.
16. Zhang JJ, Cao Y, Dong X, et al. Distinct characteristics of COVID-19
patients with initial rRT-PCR-positive and rRT-PCR-negative results for
SARS-CoV-2. Allergy. 2020. DOI: 10.1111/all.14316.
17. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for
mortality of adult inpatients with COVID-19 in Wuhan, China: a
retrospective cohort study. Lancet. 2020 Mar 11. pii:
S0140-6736(20)30566-3. doi: 10.1016/S0140-6736(20)30566-3.
18. Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in
adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020 Apr 12.
pii: S0091-6749(20)30495-4. doi: 10.1016/j.jaci.2020.04.006.
19. Guan WJ, Liang WH, Zhao Y, et al; China Medical Treatment Expert
Group for Covid-19. Comorbidity and its impact on 1590 patients with
Covid-19 in China: A nationwide analysis. Eur Respir J. 2020 Mar 26.
pii: 2000547. doi: 10.1183/13993003.00547-2020.
20. Onder G, Rezza G, Brusaferro S. Case-fatality rate and
characteristics of patients dying in relation to COVID-19 in Italy.
JAMA. 2020 Mar 23. doi: 10.1001/jama.2020.4683.
21. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L,
Castelli A. Baseline characteristics and outcomes of 1591 patients
infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy.
JAMA. 2020 Apr 6. doi: 10.1001/jama.2020.5394.
22. Niccolò Parri, Matteo Lenge, Danilo Buonsenso, for the Coronavirus
Infection in Pediatric Emergency Departments (CONFIDENCE) Research
Group. Children with Covid-19 in pediatric emergency departments in
Italy. N Engl J Med. 2020. DOI: 10.1056/NEJMc2007617.
23. Borobia AM, Carcas AJ, Arnalich F, et al; for the COVID@HULP Working
Group. A cohort of patients with COVID-19 in a major teaching hospital
in Europe. 2000 May 6. medRxiv preprint doi:https://doi.org/10.1101/2020.04.29.20080853.
24. Prieto-Alhambra D, Balló E, Coma E, et al. Hospitalization and
30-day fatality in 121,263 COVID-19 outpatient cases. 2020 May 8.
medRxiv preprint doi:https://doi.org/10.1101/2020.05.04.20090050.
25. Regina J, Papadimitriou-Olivgeris M, Burger R, Filippidis P, Tschopp
J, Desgranges F. Epidemiology, risk factors and clinical course of
SARS-CoV-2 infected patients in a Swiss university hospital: an
observational retrospective study. 2020 May 14. medRxiv preprint doi:https://doi.org/10.1101/2020.05.11.20097741.
26. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically
ill patients in the Seattle Region — Case series. N Engl J Med. 2020;
DOI: 10.1056/NEJMoa2004500.doi.
27. Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21
critically ill patients with COVID-19 in Washington State. JAMA. 2020
Mar 19. doi: 10.1001/jama.2020.4326. [Epub ahead of print]
28. CDC COVID-19 Response Team. Coronavirus Disease 2019 in Children -
United States, February 12-April 2, 2020. MMWR Morb Mortal Wkly Rep.
2020;69(14):422-426.
29. Myers LC, Parodi SM, Escobar GJ, Liu VX. Characteristics of
hospitalized adults with COVID-19 in an integrated health care system in
California. JAMA. 2020 Apr 24. doi: 10.1001/jama.2020.7202.
30. Garg S, Kim L, Whitaker M, et al. Hospitalization rates and
characteristics of patients hospitalized with laboratory-confirmed
Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30, 2020.
MMWR Morb Mortal Wkly Rep. 2020;69(15):458-464.
31. Gold JAW, Wong KK, Szablewski CM, et al. Characteristics and
clinical outcomes of adult patients hospitalized with COVID-19 —
Georgia, March 2020. MMWR. 2020;69(18):545-550.
32. Richardson S, Hirsch JS, Narasimhan M, et al; the Northwell COVID-19
Research Consortium. Presenting characteristics, comorbidities, and
outcomes among 5700 patients hospitalized with COVID-19 in the NewYork
City area. JAMA. 2020. doi:10.1001/jama.2020.6775.
33. Paranjpe I, Russak AJ, De Freitas JK, Lala A, Miotto R, Vaid A.
Clinical characteristics of hospitalized Covid-19 patients in New York
City. 2020 April 26. medRxiv preprint doi:
https://doi.org/10.1101/2020.04.19.20062117.
34. Argenziano MG, Bruce SL, Slater CL, Tiao JR, Baldwin MR, Hamilton
GR, et al. Characterization and clinical course of 1000 patients with
COVID-19 in New York: retrospective case series. 2020 May 7. medRxiv
preprint doi: https://doi.org/10.1101/2020.04.20.20072116.
35. Docherty AB, Harrison EM, Green CA, et al. Features of 16,749
hospitalised UK patients with COVID-19 using the ISARIC WHO clinical
characterisation protocol. medRxiv (2020)
doi:10.1101/2020.04.23.20076042.
36. Williamson E, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE;
The OpenSAFELY Collaborative. OpenSAFELY: factors associated with
COVID-19-related hospital death in the linked electronic health records
of 17 million adult NHS patients. 2020 May 7. doi:
https://doi.org/10.1101/2020.05.06.20092999. medRxiv preprint.
37. Khawaja AP, Warwick AN, Hysi PG, et al. Associations with covid-19
hospitalisation amongst 406,793 adults: the UK Biobank prospective
cohort study. 2020 May 11. medRxiv preprint doi:
https://doi.org/10.1101/2020.05.06.20092957.
38. Atkins JL, Masoli JÁ, Delgado J, et al. Preexisting comorbidities
predicting severe COVID-19 in older adults in the UK Biobank community
cohort. 2020 May 8. medRxiv preprint doi:
https://doi.org/10.1101/2020.05.06.20092700.
39. Shabrawishi M, Al-Gethamy MM, Naser AY, et al. Clinical,
Radiological and therapeutic characteristics of patients with COVID-19
in Saudi Arabia. 2020 May 12. edRxiv preprint doi:
https://doi.org/10.1101/2020.05.07.20094169.
40. Carrillo-Veja MF, Salinas-Escudero G, García-Peña C,
Gutiérrez-Robledo LM, Parra-Rodríguez L. Early estimation of the risk
factors for hospitalisation and mortality by COVID-19 in México. 2020
May 14. medRxiv preprint doi:
https://doi.org/10.1101/2020.05.11.20098145.
41. FluView interactive: laboratory-confirmed influenza
hospitalizations. Atlanta, GA: US Department of Health and Human
Services, CDC; 2020. https://www.cdc.gov/flu/weekly/
fluviewinteractive.htm ref (Accessed 24-April-2020).
42. Johnston SL, Pattemore PK, Sanderson G, et al. Community study of
role of viral infections in exacerbations of asthma in 9–11 year old
children. BMJ. 1995;310:1225–1229.
43. Papadopoulos NG, Christodoulou I, Rohde G, et al. Viruses and
bacteria in acute asthma exacerbations—a GA2LEN-DARE systematic
review. Allergy. 2011;66:458–468.
44. Satia I, Cusack R, Greene JM, O’Byrne PM, Killian KJ, Johnston N.
Prevalence and contribution of respiratory viruses in the community to
rates of emergency department visits and hospitalizations with
respiratory tract infections, chronic obstructive pulmonary disease and
asthma. PLoS One. 2020;15(2):e0228544.
45. Zheng X-Y, Xu Y-J, Guan W-J, Lin L-F. Regional, age and
respiratory-secretion-specific prevalence of respiratory viruses
associated with asthma exacerbation: a literature review. Arch Virol.
2018;163(4):845-853.
46. van Bever HP, Chng SY, Goh DY. Childhood severe acute respiratory
syndrome, coronavirus infections and asthma. Pediatr Allergy Immunol.
2004;15(3):206-209.
47. Tokuhira N, Shime N, Inoue M, et al, Writing Committee of AH1N1
Investigators; Japanese Society of Intensive Care Medicine Pediatric
Intensive Care Unit Network. Mechanically ventilated children with 2009
pandemic Influenza A/H1N1: results from the national pediatric intensive
care registry in Japan. Pediatr Crit Care Med. 2012;13(5):294-298.
48. Ludvigsson JF. Systematic review of COVID-19 in children show milder
cases and a better prognosis than adults. Acta Paediatr. 2020 Mar 23.
doi: 0.1111/apa.15270.
49. Woodruff PG, Modrek B, Choy DF, et al. T-helper Type 2-driven
inflammation defines major subphenotypes of asthma. Am J Resp Crit Care
Med. 2009;180:388-395.
50. Zhu J, Ji P, Pang J, et al. Clinical characteristics of 3,062
COVID-19 patients: a meta-analysis. J Med Virol. 2020 Apr 15. doi:
10.1002/jmv.25884.
51. Morais-Almeida M, Aguiar R, Martin B, et al. COVID-19, asthma and
biologic therapies: what we need to know. World Allergy Organ J. 2020
(in press ).
52. Sajuthi SP, DeFord P, Jackson ND, et al. Type 2 and interferon
inflammation strongly regulate SARS- CoV-2 related gene expression in
the airway epithelium. bioRxiv 2020.2020.04.09.034454.
53. Jackson DJ, Busse WW, Bacharier LB, et al. Association of
respiratory allergy, asthma and expression of the SARS-CoV-2 receptor,
ACE2. J Allergy Clin Immunol. 2020, doi:
https://doi.org/10.1016/j.jaci.200.04.009.
54. Peters MC, Sajuthi S, Deford P, et al. SARS-COV-2 Related Genes in
Sputum Cells in Asthma: Relationship to Demographic Features and
Corticosteroids. Am J Respir Crit Care Med. 2020 Apr 29. doi:
10.1164/rccm.202003-0821OC.
55. Yamaya M, Nishimura H, Deng X, et al. Inhibitory effects of
glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E
replication and cytokine production by primary cultures of human nasal
and tracheal epithelial cells. Respir Investig. 2020. Epub 2020/02/26.
56. Matsuyama S, Kawase M, Nao N, et al. The inhaled corticosteroid
ciclesonide blocks coronavirus RNA replication by targeting viral NSP15.
bioRxiv. 2020:2020.03.11.987016.
57. Jeon S, Ko M, Lee J, et al. Identification of antiviral drug
candidates against SARS-CoV-2 from FDA-approved drugs. bioRxiv.
2020:2020.03.20.999730.
58. Dong X, Cao YY, Lu XX, et al. Eleven faces of coronavirus disease
2019. Allergy. 2020 Mar 20. doi: 10.1111/all.14289.
59. Global Initiative for Asthma. 2020 GINA Report, Global Strategy for
Asthma Management and Prevention 2020. Available from:www.ginasthma.org (Accessed
28-Apr-2020).
60. Halpin DMG, Singh D, Hadfield RM. Inhaled corticosteroids and
COVID-19: a systematic review and clinical perspective. Eur Respir J.
2020 Apr 27. pii: 2001009. doi: 10.1183/13993003.01009-2020.
61. Klimek L, Jutel M, Akdis C, at al. Handling of allergen
immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement. Klimek
L, Jutel M, Akdis C, at al. Allergy. 2020 Apr 24. doi:
10.1111/all.14336.
62. Bousquet J, Akdis C, Jutel M, et al; ARIA-MASK study group.
Intranasal corticosteroids in allergic rhinitis in COVID-19 infected
patients: An ARIA-EAACI statement. Allergy. 2020 Mar 31. doi:
10.1111/all.14302.
63. Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid
treatment on plasma SARS-associated Coronavirus RNA concentrations in
adult patients. J Clin Virol. 2004;31(4):304-309.
64. Arabi YM, Mandourah Y, Al-Hameed F, et al; Saudi Critical Care Trial
Group. Corticosteroid therapy for critically ill patients with Middle
East Respiratory Syndrome. Am J Respir Crit Care Med.
2018;197(6):757-767.
65. Levin M, Morais-Almeida M, Ansotegui I, et al. Acute asthma
management during SARS-CoV2-pandemic 2020. World Allergy Organ J. 2020
May 14:100125. doi: 10.1016/j.waojou.2020.100125.
66. Kaye L, Theye B, Smeenk I, Gondalia R, Barrett MA, Stempel DA. J
Alllergy Clin Immunol Practice. 2020.
https://doi.org/10.1016/j.jaip.2020.04.053.